Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JOTROL in Healthy Subjects
NCT04668274Phase 1Completed
- Sponsor
- Jupiter Neurosciences, Inc.
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of resveratrol in Alzheimer's disease (AD) (4 arms), sponsored by Jupiter Neurosciences, Inc. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 131 days, Area Under the Plasma Concentration-time Curve From Time 0 to Time of Infinity at Day 1 and 2 more. Started Jan 2021; status: completed.
02
Drugs
resveratrol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04668274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668274.